354 related articles for article (PubMed ID: 34906767)
1. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
3. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
4. NK Cell-Based Immune Checkpoint Inhibition.
Khan M; Arooj S; Wang H
Front Immunol; 2020; 11():167. PubMed ID: 32117298
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
6. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
7. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
8. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
9. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
10. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
11. Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors.
Davar D; Zarour HM
Methods Mol Biol; 2020; 2055():23-60. PubMed ID: 31502146
[TBL] [Abstract][Full Text] [Related]
12. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer.
Buckle I; Guillerey C
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503073
[TBL] [Abstract][Full Text] [Related]
14. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
15. Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
Shek D; Read SA; Akhuba L; Qiao L; Gao B; Nagrial A; Carlino MS; Ahlenstiel G
Immunotherapy; 2020 May; 12(7):513-529. PubMed ID: 32378480
[TBL] [Abstract][Full Text] [Related]
16. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?
Hosseinkhani N; Derakhshani A; Kooshkaki O; Abdoli Shadbad M; Hajiasgharzadeh K; Baghbanzadeh A; Safarpour H; Mokhtarzadeh A; Brunetti O; Yue SC; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167514
[TBL] [Abstract][Full Text] [Related]
18. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
20. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
